Big Pharma CEOs push hard for tax reform and a proposed border levy
Big biopharma is bullish on the prospects of tax reform under the Trump administration. And it wants to get a deal done ASAP.
In a letter addressed by a lineup of corporate CEOs — including Eli Lilly’s David Ricks, Pfizer’s Ian Read, Ken Frazier from Merck and Mark Alles at Celgene — the group billing itself as the “American Made Coalition” urged leaders of the House and Senate to rally around a reform plan that would allow for the repatriation of billions of dollars in overseas accounts and a lower tax rate for all companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
